Literature DB >> 23187748

Neither FDG-PET Nor CT can distinguish between a pathological complete response and an incomplete response after neoadjuvant chemoradiation in locally advanced rectal cancer: a prospective study.

José G Guillem1, Jeannine A Ruby, Tobias Leibold, Timothy J Akhurst, Henry W Yeung, Marc J Gollub, Michelle S Ginsberg, Jinru Shia, Arief A Suriawinata, Elyn R Riedel, Madhu Mazumdar, Leonard B Saltz, Bruce D Minsky, Garrett M Nash, Philip B Paty, Larissa K Temple, Martin R Weiser, Steven M Larson.   

Abstract

OBJECTIVE: To prospectively compare the ability of flourodeoxyglucose-positron emission tomography (FDG-PET) and computed tomography (CT) to identify a pathological complete response (pCR) in patients with rectal cancer treated by chemoradiation.
BACKGROUND: A major obstacle in pursuing nonoperative management in patients with rectal cancer after chemoradiation is the inability to identify a pCR preoperatively.
METHODS: A total of 121 patients with rectal cancer were prospectively enrolled. FDG-PET scans and helical CT scans were obtained before and after neoadjuvant chemoradiation. Consensus readings of PET and CT scans were used to classify certainty of disease (5-point confidence rating scale). The ability of PET and CT scans to accurately distinguish a pCR (ypT0) from an incomplete response (ypT1-4) was estimated using the area under the receiver operating characteristic curve (AUC).
RESULTS: Of the 121 patients, 26 (21%) had a pCR. PET and CT scans were equally inadequate at distinguishing a pCR from an incomplete response (AUC = 0.64 for both, P = 0.97). Among the 26 patients with a pCR, 14 (54%) and 5 (19%) were classified as complete responders on PET and CT scans, respectively. Among the 95 patients with an incomplete pathological response, 63 (66%) and 90 (95%) were classified as incomplete responders on PET and CT scans, respectively. None of the individual PET parameters, including visual response score, mean standard uptake value (SUVmean), maximum SUV (SUVmax), and total lesion glycolysis, accurately distinguished a pCR (AUCs = 0.57-0.73).
CONCLUSIONS: Neither PET nor CT scans have adequate predictive value to be clinically useful in distinguishing a pCR from an incomplete response and, therefore, should not be obtained for the purpose of attempting to predict a pCR after neoadjuvant chemoradiation for rectal cancer.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23187748     DOI: 10.1097/SLA.0b013e318277b625

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  35 in total

Review 1.  Recent developments in colorectal imaging.

Authors:  Perry J Pickhardt
Journal:  Curr Opin Gastroenterol       Date:  2015-01       Impact factor: 3.287

2.  Impact of PET/CT for Restaging Patients With Locally Advanced Rectal Cancer After Neoadjuvant Chemoradiation.

Authors:  Eric Sorenson; Fernando Lambreton; Jian Q Yu; Tianyu Li; Crystal S Denlinger; Joshua E Meyer; Elin R Sigurdson; Jeffrey M Farma
Journal:  J Surg Res       Date:  2019-06-21       Impact factor: 2.192

3.  Locally advanced rectal cancer: is diffusion weighted MRI helpful for the identification of complete responders (ypT0N0) after neoadjuvant chemoradiation therapy?

Authors:  S Sassen; M de Booij; M Sosef; R Berendsen; G Lammering; R Clarijs; M Bakker; R Beets-Tan; F Warmerdam; R Vliegen
Journal:  Eur Radiol       Date:  2013-07-06       Impact factor: 5.315

Review 4.  Non-operative management of rectal cancer: understanding tumor biology.

Authors:  Iris H Wei; Julio Garcia-Aguilar
Journal:  Minerva Chir       Date:  2018-05-24       Impact factor: 1.000

Review 5.  How Should Imaging Direct/Orient Management of Rectal Cancer?

Authors:  Jemma Bhoday; Svetlana Balyasnikova; Anita Wale; Gina Brown
Journal:  Clin Colon Rectal Surg       Date:  2017-11-27

Review 6.  Multimodal imaging evaluation in staging of rectal cancer.

Authors:  Suk Hee Heo; Jin Woong Kim; Sang Soo Shin; Yong Yeon Jeong; Heoung-Keun Kang
Journal:  World J Gastroenterol       Date:  2014-04-21       Impact factor: 5.742

7.  Human cytomegalovirus and Epstein-Barr virus infection impact on (18)F-FDG PET/CT SUVmax, CT volumetric and KRAS-based parameters of patients with locally advanced rectal cancer treated with neoadjuvant therapy.

Authors:  Claudio V Sole; Felipe A Calvo; Carlos Ferrer; Emilio Alvarez; Jose L Carreras; Enrique Ochoa
Journal:  Eur J Nucl Med Mol Imaging       Date:  2014-10-01       Impact factor: 9.236

Review 8.  Predicting complete response: is there a role for non-operative management of rectal cancer?

Authors:  T Jonathan Yang; Karyn A Goodman
Journal:  J Gastrointest Oncol       Date:  2015-04

Review 9.  Advances and challenges in treatment of locally advanced rectal cancer.

Authors:  J Joshua Smith; Julio Garcia-Aguilar
Journal:  J Clin Oncol       Date:  2015-04-27       Impact factor: 44.544

10.  Local excision of low rectal cancer treated by chemoradiotherapy: is it safe for all patients with suspicion of complete tumor response?

Authors:  Clotilde Debove; Nathalie Guedj; Ecoline Tribillon; Léon Maggiori; Magaly Zappa; Yves Panis
Journal:  Int J Colorectal Dis       Date:  2016-03-07       Impact factor: 2.571

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.